Published in Hum Mol Genet on July 29, 2009
Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One (2011) 1.51
Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One (2013) 1.43
SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet (2010) 1.30
Combining comparative proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degeneration in vivo. PLoS Genet (2012) 1.04
Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One (2012) 0.92
Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol (2011) 0.92
An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci (2014) 0.91
Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab (2012) 0.91
Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis (2012) 0.89
Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis (2010) 0.89
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis (2016) 0.88
Synaptic protection in the brain of WldS mice occurs independently of age but is sensitive to gene-dose. PLoS One (2010) 0.87
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. PLoS One (2013) 0.82
A guide to modern quantitative fluorescent western blotting with troubleshooting strategies. J Vis Exp (2014) 0.81
Altered glutamate receptor function in the cerebellum of the Ppt1-/- mouse, a murine model of infantile neuronal ceroid lipofuscinosis. J Neurosci Res (2011) 0.81
Identifying cellular pathways modulated by Drosophila palmitoyl-protein thioesterase 1 function. Neurobiol Dis (2010) 0.80
Morphologic and functional correlates of synaptic pathology in the cathepsin D knockout mouse model of congenital neuronal ceroid lipofuscinosis. J Neuropathol Exp Neurol (2011) 0.79
Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. Acta Neuropathol Commun (2015) 0.78
Expression of the neuroprotective slow Wallerian degeneration (WldS) gene in non-neuronal tissues. BMC Neurosci (2009) 0.78
Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. Neurogenetics (2015) 0.77
Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging. PLoS One (2015) 0.77
Proteomic Profiling of Cranial (Superior) Cervical Ganglia Reveals Beta-Amyloid and Ubiquitin Proteasome System Perturbations in an Equine Multiple System Neuropathy. Mol Cell Proteomics (2015) 0.77
Molecular neuropathology of the synapse in sheep with CLN5 Batten disease. Brain Behav (2015) 0.76
Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease). J Child Neurol (2013) 0.76
The Batten disease Palmitoyl Protein Thioesterase 1 gene regulates neural specification and axon connectivity during Drosophila embryonic development. PLoS One (2010) 0.76
A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLoS One (2013) 0.76
Comprehensive functional characterization of murine infantile Batten disease including Parkinson-like behavior and dopaminergic markers. Sci Rep (2015) 0.75
Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivo. Sci Rep (2017) 0.75
Synergistic effects of treating the spinal cord and brain in CLN1 disease. Proc Natl Acad Sci U S A (2017) 0.75
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
The efficiency of systematic sampling in stereology and its prediction. J Microsc (1987) 10.24
Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol (2004) 6.26
Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science (1995) 4.55
The Drosophila cell corpse engulfment receptor Draper mediates glial clearance of severed axons. Neuron (2006) 4.13
Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature (1995) 3.78
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci (1989) 3.24
Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet (2007) 3.09
Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol (2003) 2.57
Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc Natl Acad Sci U S A (2001) 2.14
Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A (2005) 2.10
Mitotic mechanisms in Alzheimer's disease? J Cell Biol (1996) 2.00
Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol (2003) 1.92
Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics (2005) 1.88
Neuroinflammation in Alzheimer's disease and prion disease. Glia (2002) 1.86
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2004) 1.75
Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia (2002) 1.74
Neuronal ceroid-lipofuscinoses in childhood. Brain Dev (1988) 1.73
Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2006) 1.69
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr Biol (2004) 1.55
The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci (2003) 1.53
The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet (2001) 1.52
Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol (2006) 1.49
Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A (2004) 1.48
A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. Eur J Neurosci (2005) 1.39
Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics (2007) 1.35
The neuronal ceroid-lipofuscinoses. J Child Neurol (1995) 1.33
Stress-inducible, murine protein mSTI1. Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases. J Biol Chem (1997) 1.33
Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res (2004) 1.32
CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum Mol Genet (2001) 1.30
Infantile type of so-called neuronal ceroid-lipofuscinosis. 2. Morphological and biochemical studies. J Neurol Sci (1973) 1.28
Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies. Acta Neuropathol (1973) 1.27
Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol (2003) 1.27
Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2004) 1.25
Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells (2004) 1.22
Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet (2001) 1.21
Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL). Hum Mol Genet (2001) 1.21
Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am J Med Genet (1998) 1.21
Neuroprotection after transient global cerebral ischemia in Wld(s) mutant mice. J Cereb Blood Flow Metab (2004) 1.20
Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain (2006) 1.20
Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J Cereb Blood Flow Metab (2002) 1.17
Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr Opin Neurol (2003) 1.15
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther (2005) 1.15
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. J Clin Invest (2008) 1.12
CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res (2004) 1.10
Age-dependent synapse withdrawal at axotomised neuromuscular junctions in Wld(s) mutant and Ube4b/Nmnat transgenic mice. J Physiol (2002) 1.10
Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J Neuropathol Exp Neurol (2008) 1.07
Delayed wallerian degeneration in the central nervous system of Ola mice: an ultrastructural study. J Neurol Sci (1992) 1.05
Progressively reduced synaptic vesicle pool size in cultured neurons derived from neuronal ceroid lipofuscinosis-1 knockout mice. Neurobiol Dis (2005) 1.04
Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem (2004) 1.04
Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds). Genome Biol (2008) 1.02
Regulation of macrophage inflammatory protein-1alpha mRNA by oxidative stress. J Biol Chem (1996) 1.01
Loss of translation elongation factor (eEF1A2) expression in vivo differentiates between Wallerian degeneration and dying-back neuronal pathology. J Anat (2008) 1.01
Neuronal expression of cell cycle-related proteins after brain ischaemia in man. Neurosci Lett (2003) 0.99
Brain gene expression profiles of Cln1 and Cln5 deficient mice unravels common molecular pathways underlying neuronal degeneration in NCL diseases. BMC Genomics (2008) 0.94
Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis. Brain Pathol (2006) 0.92
Gene expression profiling in a mouse model of infantile neuronal ceroid lipofuscinosis reveals upregulation of immediate early genes and mediators of the inflammatory response. BMC Neurosci (2007) 0.91
Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue. J Neurochem (2007) 0.87
Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2. J Neurosci Res (2009) 0.87
Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). Curr Mol Med (2002) 0.80
Neuronal ceroid lipofuscinoses in childhood. Suppl Clin Neurophysiol (2000) 0.78
Gene expression profiling in vLINCL CLN6-deficient fibroblasts: Insights into pathobiology. Biochim Biophys Acta (2006) 0.77
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet (2007) 3.09
Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell (2012) 2.11
Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol (2006) 2.03
The discovery of new deep-sea hydrothermal vent communities in the southern ocean and implications for biogeography. PLoS Biol (2012) 1.93
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther (2008) 1.82
Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet (2009) 1.76
Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2004) 1.75
Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2006) 1.69
Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology (2006) 1.69
CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther (2005) 1.66
Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med (2012) 1.63
Maternal antibrain antibodies in autism. Brain Behav Immun (2006) 1.62
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 1.56
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci (2004) 1.56
In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells (2006) 1.56
WldS prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr Biol (2012) 1.55
Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One (2011) 1.51
CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res (2005) 1.51
Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J Clin Invest (2008) 1.51
Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J Immunol (2004) 1.50
Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol (2006) 1.49
The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain (2005) 1.46
Patterns of bacterial diversity across a range of Antarctic terrestrial habitats. Environ Microbiol (2007) 1.46
Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci (2004) 1.45
Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One (2013) 1.43
Homogeneous polymerase chain reaction nucleobase quenching assay to detect the 1-kbp deletion in CLN3 that causes Batten disease. J Mol Diagn (2004) 1.42
Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res (2008) 1.42
Central amygdala glucocorticoid receptor action promotes fear-associated CRH activation and conditioning. Proc Natl Acad Sci U S A (2008) 1.41
AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther (2005) 1.41
Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol Ther (2007) 1.40
A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. Eur J Neurosci (2005) 1.39
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol (2012) 1.36
Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics (2007) 1.35
You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol Aging (2006) 1.34
Reelin signaling is impaired in autism. Biol Psychiatry (2005) 1.33
Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res (2004) 1.32
Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum Mol Genet (2011) 1.32
SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet (2010) 1.30
Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells (2007) 1.30
Effects of cis-regulatory variation differ across regions of the adult human brain. Hum Mol Genet (2010) 1.27
The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem (2003) 1.27
High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem (2005) 1.27
VAPB interacts with and modulates the activity of ATF6. Hum Mol Genet (2008) 1.26
Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells (2009) 1.26
Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum Mol Genet (2009) 1.26
Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2004) 1.25
Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell (2009) 1.25
An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet (2002) 1.24
Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet (2013) 1.23
Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One (2007) 1.23
Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J (2011) 1.22
Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem Biophys Res Commun (2009) 1.21
AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther (2005) 1.20
Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain (2006) 1.20
A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc Natl Acad Sci U S A (2003) 1.18
Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res (2005) 1.17
Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther (2010) 1.16
Lysosomal dysfunction results in altered energy balance. J Biol Chem (2007) 1.15
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther (2005) 1.15
The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech (2011) 1.15
Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol Dis (2005) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol Dis (2006) 1.14
Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood (2003) 1.13
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp Neurol (2009) 1.13
Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. Acta Neuropathol (2010) 1.13
The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus. Mol Biol Cell (2005) 1.13
mGluR5 regulates glutamate-dependent development of the mouse somatosensory cortex. J Neurosci (2008) 1.12
Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells (2008) 1.12
The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J Neurosci (2011) 1.12
Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy. J Neurosci (2011) 1.12
Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies. J Child Neurol (2007) 1.11
Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol Dis (2005) 1.11
Immunosuppression alters disease severity in juvenile Batten disease mice. J Neuroimmunol (2011) 1.10
The biodiversity and ecology of Antarctic lakes: models for evolution. Philos Trans R Soc Lond B Biol Sci (2007) 1.09
Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis (2006) 1.08
Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One (2012) 1.08
Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res (2009) 1.08
Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole. J Biol Chem (2006) 1.08
Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Invest (2014) 1.08
Defective lysosomal arginine transport in juvenile Batten disease. Hum Mol Genet (2005) 1.08